Shareholders that lost money on Edwards Lifesciences Corporation (EW) should contact Levi & Korsinsky about pending Class Action - EW

Core Viewpoint - Edwards Lifesciences Corporation is facing a class action securities lawsuit due to alleged securities fraud that impacted investors between February 6, 2024, and July 24, 2024 [1] Group 1: Lawsuit Details - The lawsuit claims that the defendants misled investors regarding Edwards' expected revenue for fiscal year 2024, particularly concerning the growth of the Transcatheter Aortic Valve Replacement (TAVR) platform [2] - On July 24, 2024, Edwards reported disappointing financial results for Q2 2024 and significantly reduced its revenue guidance for the TAVR platform for the full fiscal year 2024 [2] - The company attributed the TAVR setback to the growth of structural heart therapies, which strained hospital workflows and led to underutilization of TAVR despite claims of an undertreated patient population [2] Group 2: Market Reaction - Following the announcement of the financial results and revenue guidance cut, Edwards' stock price plummeted from $86.95 per share on July 24, 2024, to $59.70 per share on July 25, 2024, marking a decline of approximately 31.34% in one day [2] Group 3: Next Steps for Investors - Investors who suffered losses during the relevant period have until December 13, 2024, to request appointment as lead plaintiff in the lawsuit [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] Group 4: Firm Background - Levi & Korsinsky has a history of securing significant settlements for shareholders and has been recognized as one of the top securities litigation firms in the United States [4]